The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...

However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...

WASHINGTON/NEW YORK, Nov 15 (Reuters) - Robert F. Kennedy Jr. vowed to purge the U.S. Food and Drug Administration shortly before being chosen as President-elect Donald Trump's nominee for ...

In September, the FDA approved the first new schizophrenia treatment in decades. 1 Cobenfy (xanomeline and trospium chloride) has a new mechanism of action, and there is a lot of potential for ...

The FDA's proposal comes more than a year after the agency's outside advisers voted against continued use of the ingredient, called oral phenylephrine, citing concerns with the initial data used ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

(The Hill) — The Food and Drug Administration (FDA) is proposing the removal from the market of a common ingredient found in most oral over-the-counter cold medicines because it doesn’t work. The move ...